How Can We Help You?
At swii.ch, we help rare disease teams move from insight to impact — faster. Whether you’re identifying patients, building advocacy, or preparing for JCA, our services are designed to accelerate access and amplify patient voice.
JCA Readiness
Operationalise your JCA strategy with confidence. We help you align affiliates, predict PICOs, and generate HTA-grade patient evidence — all powered by our modular RAREready system.
Patient Identification
Find and engage the right patients earlier. We combine behavioural science, digital tools, and data analytics to uncover hidden populations and accelerate diagnosis in rare disease.
Advocacy & Education
Build trust that lasts. We co-create with patient communities to design awareness campaigns, education programs, and advocacy ecosystems that drive action and improve access.
Digital-first. Insight-led. Built for rare disease complexity.
At swii.ch, we go beyond traditional engagement. Our approach blends behavioural science, digital innovation, and strategic consultancy to solve the toughest challenges in rare disease. From cross-border coordination to patient co-creation, we design systems — not just services — that accelerate access, build trust, and deliver measurable impact.
What Our Clients Say
I have been engaging with swii.ch in the last 18 months to utilise their services in patient engagement and consultancy. Throughout this time, they have delivered to me qualitative analyses, patient group research and strategic advice, and will be supporting me with various patient and access-related activities.
I would not hesitate to recommend the team for their experience, counsel, transparency, delivery and ability to build good relationships with people both in and outside the company.
Vice President EMEA – Lupin Neurosciences
We chose to work with swii.ch as they demonstrated their unique approach of combining years of patient engagement experience with technical/digital competencies to ensure patients remain central to the solutions we develop.
At the time we were planning to develop a roadmap for our digital strategy for an ultra-rare neuromuscular disease, and the approach swii.ch recommended allowed us to develop a good understanding of the patient’s digital journey for information that enabled us to identify the gaps that exist in the specific disease area. Swii.ch effectively guided the team’s creative thinking around insights gathered through the first phase of the project which enabled us to deliver a plan to develop a structured digital ecosystem that we believe will empower patients and their families/caregivers with information and solutions to live their best lives.
Director of Patient Engagement and Advocacy EMEA Alnylam Pharmaceuticals Europe
Rare Insights
From JCA readiness to patient engagement, our team shares what’s working — and what’s next — in rare disease access.
AI, Rare Disease Research, and the Risks of “Synthetic Patients”
Artificial intelligence (AI) is beginning to find its place in rare disease research. With small populations, fragmented registries, and[…]
EU Joint Clinical Assessment: What Sponsors Need to Know in 2025
The Joint Clinical Assessment (JCA) came into force in January 2025. It begins with oncology and advanced therapies and will expand:[…]
5 Misconceptions About Patient Engagement in JCA – And Why Early Access Could Be Your Advantage
As EU HTA evolves under the Joint Clinical Assessment (JCA), the expectations for structured, regulator-ready patient engagement are rising.[…]